文献速递前列腺增生与排尿功能障碍

维贝格龙治疗膀胱过度活动症的国际III期随机双盲安慰剂与阳性对照研究:EMPOWUR

International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR.
PubMed 文献 · J Urol · 2020-02-18

EMPOWUR研究是一项国际III期随机双盲安慰剂和阳性对照试验,评估每日一次75 mg维贝格龙治疗膀胱过度活动症(OAB)的疗效与安全性。共随机1518例患者,12周时维贝格龙较安慰剂显著减少每日排尿次数(1.8 vs 1.3,p<0.001)和急迫性尿失禁发作(2.0 vs 1.4,p<0.0001),耐受性良好。

要点

  • 维贝格龙75 mg每日一次可显著减少OAB患者排尿次数和急迫性尿失禁发作。
  • 维贝格龙在关键次要指标(急迫发作、每次排尿量等)也显著优于安慰剂。
  • 因不良事件停药率维贝格龙1.7%,与安慰剂1.1%相近,低于托特罗定3.3%。

核心结论

  • 每日一次75 mg维贝格龙可显著减少排尿次数、急迫发作和急迫性尿失禁,并增加每次排尿量。
  • 维贝格龙耐受性良好,安全性特征有利。

研究设计与样本

  • 国际III期随机双盲安慰剂和阳性对照试验。
  • 成人OAB患者每日排尿≥8.0次,按5:5:4随机分配至维贝格龙75 mg、安慰剂或托特罗定缓释4 mg。
  • 最多25%患者可为干性OAB(每日急迫性尿失禁发作<1.0次)。
  • 共随机1518例患者,90.4%完成试验。
  • 基线及第2、4、8、12周完成7天排尿日记。

主要发现

  • 12周时维贝格龙组每日排尿次数调整均值减少1.8次,安慰剂组减少1.3次(p<0.001,共同主要终点),托特罗定组减少1.6次。
  • 在尿失禁患者中,维贝格龙组每日急迫性尿失禁发作调整均值减少2.0次,安慰剂组减少1.4次(p<0.0001,共同主要终点),托特罗定组减少1.8次。
  • 维贝格龙在急迫发作次数、每次排尿量及尿失禁患者急迫性尿失禁发作减少≥75%的比例等关键次要指标上均显著优于安慰剂(所有p<0.01)。
  • 因不良事件停药率:维贝格龙1.7%,安慰剂1.1%,托特罗定3.3%。
  • 高血压发生率:维贝格龙1.7%,安慰剂1.7%。

临床怎么用

  • 对于OAB患者,可考虑每日一次75 mg维贝格龙以改善排尿次数、急迫感和急迫性尿失禁。
  • 维贝格龙因不良事件停药率低,可作为耐受性良好的治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We assessed efficacy, safety and tolerability of vibegron, a novel, potent, highly selective β3-adrenoceptor agonist, administered 12 weeks at 75 mg once daily to patients with overactive bladder in an international phase III trial with placebo and active control. MATERIALS AND METHODS: Adult patients with overactive bladder with 8.0 or more micturitions per day were randomized 5:5:4 to 75 mg vibegron, placebo or extended-release 4 mg extended-release tolterodine. Up to 25% of patients could have dry overactive bladder (less than 1.0 urge incontinence episode per day). Patients completed 7-day voiding diaries at baseline and weeks 2, 4, 8 and 12. RESULTS: Of 1,518 randomized patients 90.4% completed the trial. At 12 weeks micturitions decreased by an adjusted mean of 1.8 episodes per day for vibegron vs 1.3 for placebo (p <0.001, co-primary end point) and 1.6 for tolterodine. Among incontinent patients urge incontinence episodes decreased by an adjusted mean 2.0 episodes per day for vibegron vs 1.4 for placebo (p <0.0001, co-primary end point) and 1.8 for tolterodine. Moreover, vibegron was statistically significantly superior to placebo for key secondary measures of number of urgency episodes, volume per micturition and proportion of incontinent patients with a 75% or greater reduction in urge incontinence episodes (all p <0.01). Among vibegron treated patients 1.7% discontinued treatment because of adverse events vs 1.1% for placebo and 3.3% for tolterodine. Incidence of hypertension was 1.7% for vibegron and for placebo. CONCLUSIONS: Once daily 75 mg vibegron provided statistically significant reductions in micturitions, urgency episodes and urge incontinence, and increased the volume per micturition. Treatment was well tolerated with a favorable safety profile.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Staskin D, Frankel J, Varano S, et al. International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR. J Urol. 2020. PMID: 32068484. doi:10.1097/JU.0000000000000807

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。